Boron
Boron is a trace mineral present throughout the plant kingdom and consequently found across most diets that include adequate fruit, vegetables, nuts, and legumes. It has been studied in human nutrition for several decades, and a consistent picture has emerged: people with very low boron intake show measurable changes in hormone profiles, mineral metabolism, and cognitive function that improve when boron is restored. What remains considerably less established is whether supplementing boron in people who already consume adequate amounts from their diet produces meaningful additional benefit. This distinction is the interpretive key for most of the evidence reviewed here.
What it is
Boron is element number 5 and a metalloid — neither a metal nor a nonmetal — that functions biologically in ways that remain incompletely characterised. No RDA has been established because no essential biological function with defined deficiency consequences has been confirmed in humans; boron sits alongside a small number of trace elements that are biologically active and clearly beneficial at adequate intakes, without meeting the formal criteria for essentiality. The Food and Nutrition Board has set a Tolerable Upper Intake Level (UL) of 20 mg/day for adults but no Recommended Dietary Allowance, reflecting a body of evidence suggesting benefit at adequate intakes without a precisely defined requirement.
Dietary intake in Western populations ranges from approximately 1 to 3 mg/day in typical omnivore diets, rising to 3 mg or above in diets rich in plant foods. Avocado, dried fruits, peanuts and tree nuts, wine, grape juice, and prune juice are among the richest sources. Boron in food is absorbed as boric acid and is water-soluble, efficiently absorbed, and excreted primarily through the kidneys.
Boron's proposed biological mechanisms span several systems. It appears to influence the activity of enzymes involved in steroid hormone metabolism, prolonging the biological half-life of estradiol and testosterone and modulating conversion between active and inactive hormone forms. It reduces urinary excretion of calcium and magnesium, which has downstream effects on bone mineral density and muscle function. It influences the activation and half-life of vitamin D, potentially acting as a co-factor for the conversion of 25-hydroxyvitamin D to its active 1,25-dihydroxy form. It has anti-inflammatory activity through inhibition of NF-kB signalling and reduction of inflammatory cytokines. These mechanisms are well-characterised in controlled experimental settings; how much they matter in people already eating adequate boron is the unresolved question.
What the evidence shows
The boron literature is structured around two distinct paradigms that must be kept separate: depletion-repletion studies, in which participants are placed on controlled low-boron diets and then supplemented, and supplementation studies in people consuming typical or adequate boron from diet. The first paradigm produces consistent and meaningful results. The second is considerably less consistent, and in some domains negative. These effects demonstrate the consequences of experimental depletion rather than the benefits of supplementation in typical dietary contexts — a distinction that is essential for interpreting the evidence correctly.
Hormone profiles. The foundational human study — Nielsen et al. (1987, FASEB Journal) — enrolled 13 postmenopausal women maintained on a diet providing only 0.25 mg boron/day for 63 days, then repleted with 3 mg/day. Serum estradiol nearly doubled and testosterone more than doubled in some women, particularly those with low magnesium intake. These striking changes reflect correction of a depletion state, not enhancement beyond normal physiology. The magnitude of these changes reflects correction of experimentally induced low-status conditions rather than enhancement beyond typical physiological ranges, and they should not be generalised to people consuming adequate dietary boron.
In healthy men, Naghii et al. (2011, Journal of Trace Elements in Medicine and Biology) found that one week of 6 mg/day boron supplementation increased free testosterone from approximately 11.8 to 15.2 pg/mL and decreased estradiol, with concurrent reductions in inflammatory markers. This was a crossover study of eight men with no placebo control arm. The effect is directionally consistent with the proposed mechanism but the study is too small and methodologically limited to support conclusions.
Critically, studies in healthy athletes and bodybuilders — populations typically consuming replete diets — have not found testosterone or muscle mass improvements from boron supplementation. The Tolerable Upper Intake Level review and multiple analyses of athletic performance conclude there is no reliable evidence of ergogenic effect in replete individuals.
Bone health. Boron's effects on bone are mediated through mineral conservation and hormone modulation rather than direct bone-building activity. Boron supplementation reduces urinary calcium and magnesium excretion — a finding replicated across multiple small trials — which is mechanistically relevant to bone mineral balance. However, no adequately powered RCT has demonstrated that boron supplementation directly improves bone mineral density (BMD) in humans. Animal studies consistently show improved trabecular bone quality in boron-supplemented animals. A 10-month RCT in female athletes (n=28) found boron reduced serum phosphorus and increased magnesium but did not directly improve BMD. The bone evidence is mechanistically coherent but clinically unproven.
Joint health and inflammation. The calcium fructoborate form of boron has a small but controlled evidence base for osteoarthritis. A double-blind, placebo-controlled RCT (n=108) using 108 mg/day calcium fructoborate (yielding approximately 6 mg boron) found significant reductions in CRP, IL-6, and TNF-alpha, and meaningful improvements in WOMAC pain scores over the study period. This is a single, unreplicated RCT providing preliminary clinical outcome evidence — the most direct controlled evidence available for any boron compound, but not sufficient to establish efficacy without independent replication.
Cognitive function. The cognitive evidence comes primarily from deprivation studies. Penland (1994, Environmental Health Perspectives) conducted a controlled crossover trial in older adults on low and adequate boron diets and found that low boron intake was associated with poorer performance on tasks measuring motor speed, attention, and short-term memory, with altered EEG patterns consistent with reduced alertness. Restoring adequate boron improved these parameters. This is not evidence that supplementing above adequate intake enhances cognition in healthy people — it is evidence that boron adequacy matters for normal cognitive function, analogous to zinc or iodine in their respective domains. No controlled trial demonstrates cognitive enhancement in individuals with adequate boron intake.
Five questions
Does low status cause harm? There is consistent evidence that very low boron intake — below approximately 0.5 mg/day — is associated with measurable impairments in mineral metabolism, hormone profiles, and cognitive performance that improve with repletion. Whether this constitutes a formal deficiency state is debated because no essential biological function has been defined, but the functional consequences of sustained very low intake are reasonably well-supported. Typical Western diets provide 1–3 mg/day, which appears sufficient for most people.
Does supplementation prevent disease? No controlled human evidence demonstrates that boron supplementation prevents osteoporosis, fracture, cardiovascular disease, or cognitive decline. The mechanistic plausibility for bone protection is real, particularly through calcium and vitamin D interactions, but has not been tested in adequately powered prevention trials.
Does it affect biomarkers? Yes, in depleted individuals. Sex hormone profiles — particularly free testosterone in men and estradiol in postmenopausal women — improve on boron repletion from low-status states. Urinary calcium and magnesium excretion is reduced. Inflammatory markers including CRP, IL-6, and TNF-alpha are reduced in the calcium fructoborate arthritis trial. Vitamin D activation is enhanced in some experimental contexts. Whether these biomarker effects occur reliably in replete populations is less clearly established.
Does it help clinical populations? The most direct clinical evidence is in osteoarthritis — a single RCT with calcium fructoborate showing pain and inflammatory marker improvements. Postmenopausal women with demonstrated low boron status may benefit from repletion in terms of hormone profiles. Beyond these populations, clinical evidence is insufficient.
Does it benefit healthy individuals? For healthy individuals already consuming adequate dietary boron, supplementation evidence is largely negative for the most commonly marketed outcomes — testosterone enhancement, muscle mass, and athletic performance. The cognitive and hormonal evidence comes predominantly from depletion contexts.
Individual variation
Dietary pattern is the primary determinant of individual variation in boron status. People consuming diets low in fruits, vegetables, nuts, and legumes — including many high-protein, low-carbohydrate approaches — may have dietary boron intakes below the range associated with optimal hormonal and cognitive function. In these individuals, the evidence for benefit from supplementation is considerably stronger than in people already consuming plant-food-rich diets.
Magnesium status modifies the hormonal response to boron repletion — the Nielsen 1987 study showed larger estradiol increases in women with lower magnesium intake. This interaction suggests that boron's effects on mineral metabolism operate in the context of broader dietary mineral adequacy.
Postmenopausal women represent the population with the clearest evidence base for boron's hormonal effects, given that the original depletion-repletion research was conducted in this group and that estrogen changes at this life stage are clinically relevant. Boron supplementation does not substitute for hormone replacement therapy and should not be framed as doing so.
Sex-specific responses are documented. Men show primarily free testosterone and estradiol modulation; women show primarily estradiol and testosterone changes. These responses are most pronounced in people starting from low boron status.
Testing and status assessment
There are no clinically available tests for boron status. Urinary boron concentrations correlate with recent intake but are not available through routine clinical laboratories and have no established clinical reference range. There is no practical way to test whether an individual is boron-depleted before supplementing; dietary history and food pattern assessment provides the most clinically useful guide to likely boron adequacy.
Safety
Boron at 3–6 mg/day — the range used in most clinical trials and common supplement products — is well tolerated in healthy adults. No significant adverse events have been reported at these doses in published human studies.
The US Food and Nutrition Board established a UL of 20 mg/day for adults, based on animal reproductive and developmental toxicity data. In animal studies at high doses, boron caused testicular atrophy, impaired spermatogenesis, and fetal developmental abnormalities including skeletal malformations. These effects were observed at doses far above typical supplemental intake. Occupational exposure studies in boron industry workers — who have higher chronic exposures than supplement users — have not consistently confirmed reproductive toxicity in humans, though the human data are limited. Doses above 20 mg/day should be avoided until clearer human safety data are available, and there is no established clinical rationale for exceeding this level.
Kidney disease is a relevant consideration. Boron is excreted primarily through the kidneys, and impaired kidney function may reduce clearance and increase accumulation risk. People with chronic kidney disease should seek clinical advice before supplementing.
Acute high-dose boric acid ingestion causes toxicity including nausea, vomiting, diarrhoea, skin flushing, CNS effects including convulsions, and in extreme cases organ failure. The doses required are far above typical supplemental intake — lethal doses in adults are estimated at 15–20 g — and this is relevant primarily to accidental ingestion of boric acid household products, not supplement use.
Hormone-sensitive conditions deserve consideration given boron's effects on estradiol and testosterone. People with hormone-sensitive cancers or conditions dependent on sex hormone levels should discuss boron supplementation with a clinician before use. The long-term implications of chronic hormone modulation at supplemental doses are not established, and this uncertainty is amplified in populations where sex hormone levels are clinically managed.
What can reasonably be concluded
Boron occupies an unusual position in the supplement landscape. The evidence that boron adequacy matters for human health — particularly for mineral metabolism, sex hormone profiles, and cognitive function — is reasonably coherent and consistent in depletion contexts. For people whose diets are low in plant foods and consequently provide less than 1 mg boron/day, supplementation to bring intake to 3–6 mg/day is mechanistically rational and supported by the depletion-repletion evidence.
The claims most commonly attached to boron supplements — testosterone enhancement, muscle building, and cognitive enhancement in already-adequate individuals — are not supported by the available evidence. The testosterone increases seen in Naghii's small studies of depleted men were real but have not been reproduced in replete athletic populations. Marketing of boron as a testosterone booster for healthy men with adequate dietary intake substantially outpaces the supporting evidence.
An Emerging rating reflects genuine and mechanistically coherent effects in depleted populations, a positive clinical signal in osteoarthritis with calcium fructoborate, and a safety profile that is reassuring at typical doses. The rating does not endorse the broader marketing claims and reflects the reality that the evidence is primarily from small, short-duration depletion-repletion studies rather than clinical trials demonstrating meaningful health outcomes in typical supplement users.
Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.